Axogen

AXGN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$16.8m

Combined value at quarter end

Last quarter

0 bought

1 sold or trimmed

Price at Q2 ’26 end

$46.19

+39.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+93.6%Q3 ’24

+17.5%Q4 ’24

+12.3%Q1 ’25

-41.4%Q2 ’25

+64.4%Q3 ’25

+83.5%Q4 ’25

+1.2%Q1 ’26

+39.4%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23

1Q1 ’24

1Q2 ’24

1Q3 ’24

1Q4 ’24

1Q1 ’25

2Q2 ’25

2Q3 ’25

2Q4 ’25

2Q1 ’26

2Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Axogen.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Axogen

First Eagle Investment Management	0.0%$15.8m	$15.8m	Trimmed -3.8%	5 qtrs
Mairs & Power	0.0%$1.0m	$1.0m	Unchanged	28 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Axogen
		Bought or sold				Filing
2 Sep 2026	Tyndall Joseph A.Director	▼ Sold	3,500	$49.70	$174k	Form 4
11 Aug 2026	Wendell Amy McbrideDirector	▼ Sold	13,353	$48.42	$647k	Form 4
10 Aug 2026	Began Marc AEVP & General Counsel	▼ Sold	67,500	$47.34	$3.2m	Form 4
7 Aug 2026	Weiler Kathy JohnsonDirector	▼ Sold	14,150	$45.30	$641k	Form 4

About the company

Sector: Health care · Electromedical & Electrotherapeutic Apparatus
Incorporated in: Minnesota
Financial year ends: 31 December
Shares outstanding: 54m at 27 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$10.9m2013

$27.3m2015

$60.4m2017

$107m2019

$127m2021

$159m2023

$225m2025

Axogen revenue and net income by year
Year	Revenue	Net income
2025	$225m	−$15.7m
2024	$187m	−$10.0m
2023	$159m	−$21.7m
2022	$139m	−$28.9m
2021	$127m	−$27.0m
2020	$112m	−$23.8m
2019	$107m	−$29.1m
2018	$83.9m	−$22.4m
2017	$60.4m	−$10.4m
2016	$41.1m	−$14.4m
2015	$27.3m	−$13.4m
2014	$16.8m	−$17.7m
2013	$10.9m	−$14.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.